

SeQuent's arm Alivira gets USFDA nod

03 May 2017 | News

The facility at Visakhapatnam was inspected for the first time by the USFDA in November 2016 and has now received Establishment Inspection Report (EIR) from USFDA.



Drug firm SeQuent Scientific's arm Alivira received approval from the US health regulator for its animal health API facility in Visakhapatnam in Andhra Pradesh.

Alivira Animal Health Ltd is a wholly-owned subsidiary of SeQuent Scientific. It has six manufacturing facilities. It is a global pharmaceutical company, in the Animal Health segment, with an integrated platform in both APIs (active pharmaceutical products) and Formulations. Headquartered in Ireland, manufacturing APIs in India, formulations in Turkey and a worldwide market presence, Alivira is infusing new life into Animal Care.

The facility at Visakhapatnam was inspected for the first time by the USFDA in November 2016 and has now received Establishment Inspection Report (EIR) from the regulator.

The receipt of the EIR will enable Alivira's entry into USD 8 billion veterinary healthcare market in the US.

While the company is already working with most of the leading animal health companies the world over, this approval will enable it to expand its reach and consolidate relationship with these enterprises.